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Abstract: Schwannomatosis is a rare tumor syndrome characterized by the presence of 
multiple benign non-vestibular, non-intradermal schwannomas and by the absence of 
neurofibromatosis type 1 or 2 syndromes. Multiple schwannomas are clinically and 
genetically distinct from neurofibromatosis, and the main treatment in case of 
symptomatic lesions is represented by surgical resection. In case of asymptomatic 
lesions, the indicated treatment is neuroimaging follow-up (MRI). We are presenting 
the case of a patient with three schwannomas of the cauda equina, as well as the 
treatment strategy in the case of this rare pathology. 
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Introduction 
Schwannomatosis is a syndrome 
characterized by the existence of multiple 
schwannomas at the level of the spinal cord, 
cranial or peripheral nerves, but without the 
presence of vestibular schwannomas, 
ependymomas, meningiomas, or astrocytomas, 
which are encountered in neurofibromatosis 
type 2 (NF2) (15, 22, 25, 27, 28). Nonetheless, 
infrequently, the existence of meningiomas or 
ependymomas has been reported within 
schwannomatosis (3, 9). 
Schwannomatosis was reported for the 
first time in 1973, as neurofibromatosis type 3 
(18), and even though some researchers 
considered it to be an incomplete form, or a 
subcategory of NF2 (7), the subsequent 
genetic and molecular studies have shown 
that schwannomatosis is a separate genetic 
and clinical syndrome (13, 20, 24). 
Schwannomatosis represents 3-5% of the 
patients with schwannomas (11, 23, 24). 
Short case report 
We are presenting the case of a 59 year old 
female patient who was hospitalized for the 
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first time in 2011, at “Prof. Dr. N. Oblu” 
Clinical Emergency Hospital of Iaşi, for long 
standing low back pain and bilateral sciatica 
with insidious onset 10 months previously, as 
well as paraparesis with insidious onset 5 
months previously. The imaging explorations 
carried out in 2011 revealed three lumbar 
spinal schwannomas located at the level of the 
cauda equina (Figure 1). Moreover, the head 
and spine MRI did not detect the existence of 
other schwannomas. Surgery was performed 
with the complete resection of the 
symptomatic schwannoma (the bigger 
schwannoma) (Figure 2). The subsequent 
anatomopathological examination was of 
schwannoma with Antoni A and B regions 
(Figure 3), and the postoperative evolution 
was favourable, without neurological deficits 
or residual radicular pain. Even though the 
patient did not have clinical symptoms, she 
was monitored every year through spine MRI 
neuroimaging, which did not identify 
significant increases in the volume of the 
tumors. In 2016, the patient was admitted 
again in our neurosurgery unit for the 
occurrence of an important long standing low 
back pain and left side sciatica about 6 
months before. The lumbar spine MRI 
performed (2016) revealed the increased size 
of one of the two tumors, in comparison with 
the previous imaging explorations (2011) 
(Figure 4). Both tumors were resected (Figure 
5), and the postoperative evolution was 
favourable. Moreover, the anatomopathologic 
diagnosis of the two tumors was of 
schwannoma with Antoni A and B areas. 
 
 
Figure 1 - T1-weighted (sagittal, coronal and axial) gadolinium-enhanced MRI images (2011) in which the 3 
schwannomas of the cauda equina can be noticed 
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Figure 2 - Preoperative (A) and postoperative (B) gadolinium-enhanced MRI images (2011) 
 
 
Figure 3 - The tumour  had a biphasic feature as it was made up  of hypercellular areas (Antoni A) composed of a 
haphazard arrangement of bland cells with spindled and oval nuclei, and  myxoid hypocellular areas (Antoni B) 
with large irregularly spaced  vessels (Hematoxylin-Eosin, x100 
 
 
Figure 4 - T1-weighted (axial) gadolinium-enhanced MRI images (2011/2016) highlighting the increased size of 
one of the schwannomas 
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Figure 5 - Intraoperative appearance of the two schwannomas (A, B), postoperative appearance (C) and their 
correspondence in MRI neuroimaging (D) (the bigger schwannoma – red arrow, the smaller schwannoma – blue 
arrow) 
 
Table I 
MacCollin’s diagnostic criteria for schwannomatosis (16) 
DEFINITIVE SCHWANNOMATOSIS POSSIBLE SCHWANNOMATOSIS 
- age >30 years AND 
- two or more non-intradermal 
schwannomas, at least one with histologic 
confirmation AND no evidence of 
vestibular tumor of high-quality MRI scan 
AND no known constitutional NF2 
mutation 
- age <30 years AND
- two or more non-intradermal 
schwannomas, at least one with a histologic 
confirmation AND no evidence of a 
vestibular tumor on a high-quality MRI 
scan AND no known constitutional NF2 
mutation 
OR OR 
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- one pathologically confirmed non-
vestibular schwannoma plus a first-degree 
relative who also meets the above criteria 
 
- age >45 years AND two or more non-
intradermal schwannomas, at least one with 
histologic confirmation AND no symptoms 
of 8th nerve dysfunction AND no known 
constitutional NF2 mutation 
 OR 
 - radiographic evidence of a non-vestibular 
schwannoma and a first degree relative also 
meeting the criteria for definite 
schwannomatosis 
 
Discussion 
Spinal schwannomas are benign tumors 
that develop from the schwann cells of the 
nerves and represent approximately one third 
of all benign primary spinal tumors (17). The 
majority of schwannomas are solitary lesions 
that can affect one or several nerves (5, 10), 
but they can also be multiple, suggesting the 
presence of syndromes, the most frequent of 
which is NF2. 
Spinal schwannomas unassociated with 
neurofibromatosis was reported for the first 
time in 1993 by the American Daras M., at 
the Metropolitan Hospital from New York 
(5). 
The schwannomatosis diagnosis is 
supported by the anatomopathological 
diagnosis which, apart from the Antoni A and 
Antoni B regions (26), also highlights other 
histological findings, such as: nerve oedema, 
intraneural growth pattern and myxoid 
stroma (21). Like in NF2, the schwannomas 
are growing slowly and do not turn into 
malignant lesions (2). 
The genetics of schwannomatosis is 
complex and not yet fully understood (14), 
given that over 90% of the sporadic cases and 
50% of the familial cases of schwannomatosis 
do not have an identified genetic mutation 
(19, 20). An associated germline mutation 
inactivating the SMARCB1 gene is 
encountered in only 40-50% of the familial 
forms, and in less than 10% in the sporadic 
cases (20). Moreover, the family history is 
present only in 15-25% of the cases (20). 
The first clinical sign of patients who are 
suffering from schwannomatosis is pain on 
the tract of the implied nerve (8, 12, 16), 
unlike patients suffering from NF2, who seek 
medical care for the occurrence of 
neurological deficit, which is represented in 
95% of the cases by hearing impairment (6). 
In our patient’s case, the onset 
symptomatology was represented by long 
standing low back pain and bilateral sciatica, 
followed by the insidious onset of 
neurological deficit. 
The age of onset of schwannomatosis is 
represented by the fourth decade (1, 11, 24), 
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unlike patients with NF2, who seek medical 
care at an earlier age (5).  
Even though some criteria for diagnosing 
schwannomatosis have been proposed, they 
are currently unclear. In 1997, Jacoby et al. 
proposed as a criterion for schwannomatosis 
the presence of 2 or more schwannomas, in 
the absence of vestibular schwannomas, in 
patients over the age of 18 (13). Later on, in 
2005, MacCollin et al. also enumerated 
several criteria: the presence of 2 or more 
non-intradermal schwannomas, over 30 years 
of age, the absence of MRI-detectible 
vestibular schwannomas, as well as the 
absence of constitutional mutations 
encountered in NF2 (Table 1) (16). The 
treatment indicated in schwannomatosis is 
the surgical removal in symptomatic cases (4) 
and follow-up in non-symptomatic cases.  
Moreover, in our patient’s case, the biggest 
schwannoma which was actually 
symptomatic, was initially resected (Figure 1, 
Figure 2). For the other two smaller, non-
symptomatic schwannomas (Figure 5), a 
conservative follow-up treatment was decided 
upon. Five years after the initial surgery, the 
patient was hospitalized for the occurrence of 
pain, due to the increased size of the second 
schwannoma. Thus, surgery with the 
complete resection of the two tumors was 
performed, having a favourable postoperative 
evolution.  
Conclusions 
In the case of multiple spinal 
schwannomas, head neuroimaging (MRI) and 
audiological testing must also be taken into 
consideration in order to exclude NF2. In 
spite of the similarities between NF2 and 
schwannomatosis, they are two distinctive 
entities, both genetically and clinically, which 
can pose diagnosis problems. The MacCollin 
criteria can be useful to differentiate between 
these two syndromes. In the case of patients 
with spinal schwannomatosis, we recommend 
surgical treatment in the case of symptomatic 
tumors, and conservative follow-up treatment 
in case nonsymptomatic tumors. 
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